跳至主要内容
临床试验/JPRN-C000000357
JPRN-C000000357已完成1 期

Evaluation of the safety and efficacy of allogenic hematopoietic stem cell transplantation (HSCT) from HLA-mismatched related donors using alemtuzumab in patients with hematological malignancies. - HLA-mismatched HSCT using alemtuzumab

GCP-ISS HE0402 group0 个研究点目标入组 48 人开始时间: 2006年3月20日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
48

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 65years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • (1)Adult T cell leukemia/lymphoma (2)Diabetes uncontrollable even with regular insulin use. (3)Uncontrollable hypertension. (4)Active infection. (5)Refractory hematological malignancies with bone marrow involvement more than 30% of tumor cells. (6)Active central nervous system involvement. (7)Current active double cancer. (8)Women who are or may be pregnant, or who are nursing. (9)Uncontrollable mental illness. (10)Hepatitis B virus antigen-positive (HBsAg or HBeAg). (11)HIV-positive. (12)A history of hypersensitivity to transplant conditioning agents (fludarabine phosphate, busulfan, cyclophosphamide) or agents for GVHD prophylaxis (ciclosporin, methotrexate). (13)A history of hematopoietic stem cell transplantation. However, a single prior autologous transplantation is permitted.

研究者

发起方
GCP-ISS HE0402 group

相似试验

Evaluation of the safety and efficacy of allogenic... | 临床试验